The Time Course of Dynamic Computed Tomographic Appearance of Radiation Injury to the Cirrhotic Liver Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Jun 13

PMID 26067065

Citations 11

Authors

Tomoki Kimura

Shigeo Takahashi

Ippei Takahashi

Ikuno Nishibuchi

Yoshiko Doi

Masahiro Kenjo

Yuji Murakami

Yohji Honda

Hiroshi Aikata

Kazuaki Chayama

Yasushi Nagata

Affiliations

Soon will be listed here.

Abstract

This study aimed to evaluate the dynamic computed tomographic (CT) appearance of focal radiation injury to cirrhotic liver tissue around the tumor following stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC). Seventy-seven patients with 92 HCCs were observed for >6 months. Sixty-four and 13 patients belonged to Child-Pugh class A and B, respectively. The median SBRT dose was 48 Gy/4fr. Dynamic CT scans were performed in non-enhanced, arterial, portal, and venous phases. The median follow-up period was 18 months. Dynamic CT appearances were classified into 3 types: type 1, hyperdensity in all enhanced phases; type 2, hypodensity in arterial and portal phases; type 3, isodensity in all enhanced phases. Half of the type 2 or 3 appearances significantly changed to type 1, particularly in patients belonging to Child-Pugh class A. After 3-6 months, Child-Pugh class B was a significant factor in type 3 patients. Thus, dynamic CT appearances were classified into 3 patterns and significantly changed over time into the enhancement group (type 1) in most patients belonging to Child-Pugh class A. Child-Pugh class B was a significant factor in the non-enhancement group (type 3).

Citing Articles

Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview.

Matsuo Y Curr Oncol. 2023; 30(2):2493-2500.

PMID: 36826151 PMC: 9956001. DOI: 10.3390/curroncol30020190.

Evolving development of multi-parametric normal tissue complication probability model for liver radiotherapy.

Tsai C, Cheng J Transl Cancer Res. 2022; 8(Suppl 2):S120-S123.

PMID: 35117079 PMC: 8797564. DOI: 10.21037/tcr.2018.11.25.

Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma.

Funaoka A, Numata K, Takeda A, Saigusa Y, Tsurugai Y, Nihonmatsu H Diagnostics (Basel). 2021; 11(3).

PMID: 33803373 PMC: 7998355. DOI: 10.3390/diagnostics11030486.

Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic.

Mehta N, Parikh N, Kelley R, Hameed B, Singal A Clin Gastroenterol Hepatol. 2020; 19(8):1520-1530.

PMID: 32652308 PMC: 7342037. DOI: 10.1016/j.cgh.2020.06.072.

Radiotherapy for HCC: Ready for prime time?.

Bang A, Dawson L JHEP Rep. 2020; 1(2):131-137.

PMID: 32039361 PMC: 7001576. DOI: 10.1016/j.jhepr.2019.05.004.

References

Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y . Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA. Int J Radiat Oncol Biol Phys. 2014; 88(2):306-11. DOI: 10.1016/j.ijrobp.2013.10.045. View

Kimura T, Takahashi S, Kenjo M, Nishibuchi I, Takahashi I, Takeuchi Y . Dynamic computed tomography appearance of tumor response after stereotactic body radiation therapy for hepatocellular carcinoma: How should we evaluate treatment effects?. Hepatol Res. 2013; 43(7):717-27. DOI: 10.1111/hepr.12007. View

Willemart S, Nicaise N, Struyven J, Van Gansbeke D . Acute radiation-induced hepatic injury: evaluation by triphasic contrast enhanced helical CT. Br J Radiol. 2000; 73(869):544-6. DOI: 10.1259/bjr.73.869.10884753. View

Hashimoto K, Murakami T, Dono K, Hori M, Kim T, Kudo M . Assessment of the severity of liver disease and fibrotic change: the usefulness of hepatic CT perfusion imaging. Oncol Rep. 2006; 16(4):677-83. View

Reichen J, Egger B, Ohara N, Zeltner T, Zysset T, Zimmermann A . Determinants of hepatic function in liver cirrhosis in the rat. Multivariate analysis. J Clin Invest. 1988; 82(6):2069-76. PMC: 442790. DOI: 10.1172/JCI113828. View

Takeda A, Takahashi M, Kunieda E, Takeda T, Sanuki N, Koike Y . Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: Preliminary results for efficacy and toxicity. Hepatol Res. 2007; 38(1):60-9. DOI: 10.1111/j.1872-034X.2007.00084.x. View

Olsen C, Welsh J, Kavanagh B, Franklin W, McCarter M, Cardenes H . Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 73(5):1414-24. DOI: 10.1016/j.ijrobp.2008.07.032. View

Kimura T, Hirokawa Y, Murakami Y, Tsujimura M, Nakashima T, Ohno Y . Reproducibility of organ position using voluntary breath-hold method with spirometer for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 60(4):1307-13. DOI: 10.1016/j.ijrobp.2004.07.718. View

Kato H, Tsujii H, Miyamoto T, Mizoe J, Kamada T, Tsuji H . Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys. 2004; 59(5):1468-76. DOI: 10.1016/j.ijrobp.2004.01.032. View

10.

Sempoux C, Horsmans Y, Geubel A, Fraikin J, Van Beers B, Gigot J . Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event. Hepatology. 1997; 26(1):128-34. DOI: 10.1002/hep.510260117. View

11.

Herfarth K, Hof H, Bahner M, Lohr F, Hoss A, Van Kaick G . Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys. 2003; 57(2):444-51. DOI: 10.1016/s0360-3016(03)00586-8. View

12.

Guha C, Kavanagh B . Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol. 2011; 21(4):256-63. PMC: 3434677. DOI: 10.1016/j.semradonc.2011.05.003. View

13.

Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T . Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement?. J Magn Reson Imaging. 2009; 30(5):1042-6. DOI: 10.1002/jmri.21956. View

14.

Leen E, Goldberg J, ANDERSON J, Robertson J, MOULE B, Cooke T . Hepatic perfusion changes in patients with liver metastases: comparison with those patients with cirrhosis. Gut. 1993; 34(4):554-7. PMC: 1374320. DOI: 10.1136/gut.34.4.554. View

15.

Okumura T, Itai Y, Tsuji H, Matsueda K, Matsuzaki Y, Tsujii H . Focused radiation hepatitis after Bragg-peak proton therapy for hepatocellular carcinoma: CT findings. J Comput Assist Tomogr. 1994; 18(5):821-3. DOI: 10.1097/00004728-199409000-00025. View

16.

Unger E, Lee J, Weyman P . CT and MR imaging of radiation hepatitis. J Comput Assist Tomogr. 1987; 11(2):264-8. DOI: 10.1097/00004728-198703000-00013. View

17.

Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M . A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009; 74(3):831-6. DOI: 10.1016/j.ijrobp.2008.10.073. View

18.

Andolino D, Johnson C, Maluccio M, Kwo P, Tector A, Zook J . Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011; 81(4):e447-53. DOI: 10.1016/j.ijrobp.2011.04.011. View

19.

Sanuki-Fujimoto N, Takeda A, Ohashi T, Kunieda E, Iwabuchi S, Takatsuka K . CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function. Br J Radiol. 2010; 83(996):1063-71. PMC: 3473607. DOI: 10.1259/bjr/74105551. View